Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Human hepatic UGT2B15 developmental expression.

Divakaran K, Hines RN, McCarver DG.

Toxicol Sci. 2014 Sep;141(1):292-9. doi: 10.1093/toxsci/kfu126. Epub 2014 Jun 30.

2.

Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP.

Gut. 2002 Feb;50(2):259-65.

3.

Human hepatic CYP2E1 expression during development.

Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG.

J Pharmacol Exp Ther. 2003 Oct;307(1):402-7. Erratum in: J Pharmacol Exp Ther. 2004 Apr;309(1):439.

4.

Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.

Hanioka N, Naito T, Narimatsu S.

Chemosphere. 2008 Dec;74(1):33-6. doi: 10.1016/j.chemosphere.2008.09.053. Epub 2008 Nov 5.

PMID:
18990428
5.

Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation.

Hanioka N, Oka H, Nagaoka K, Ikushiro S, Narimatsu S.

Arch Toxicol. 2011 Nov;85(11):1373-81. doi: 10.1007/s00204-011-0690-5. Epub 2011 Mar 15.

PMID:
21404072
6.

Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.

Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN.

Pediatr Res. 2002 Feb;51(2):236-43.

PMID:
11809920
7.

UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.

Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ.

J Pharmacol Exp Ther. 2004 Aug;310(2):656-65. Epub 2004 Mar 25.

8.

Human hepatic CYP2B6 developmental expression: the impact of age and genotype.

Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E.

Biochem Pharmacol. 2009 Jul 15;78(2):184-90. doi: 10.1016/j.bcp.2009.03.029. Epub 2009 Apr 5.

PMID:
19464434
9.

Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages.

Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, Creek MR, Clewell HJ, Yoon M.

Drug Metab Dispos. 2017 May;45(5):468-475. doi: 10.1124/dmd.116.074583. Epub 2017 Feb 22.

PMID:
28228413
11.

Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.

Miyagi SJ, Collier AC.

Drug Metab Dispos. 2007 Sep;35(9):1587-92. Epub 2007 Jun 7.

12.

Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics.

Achour B, Russell MR, Barber J, Rostami-Hodjegan A.

Drug Metab Dispos. 2014 Apr;42(4):500-10. doi: 10.1124/dmd.113.055632. Epub 2014 Jan 9.

13.

Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.

Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ.

Drug Metab Dispos. 2002 Nov;30(11):1257-65.

14.

Ontogeny of iodothyronine deiodinases in human liver.

Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, De Herder WW, den Hollander JC, Krenning EP, Visser TJ.

J Clin Endocrinol Metab. 1998 Aug;83(8):2868-74.

PMID:
9709961
15.

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T.

Eur J Biochem. 1997 Jul 15;247(2):625-34.

16.

Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus.

Ekström L, Johansson M, Rane A.

Drug Metab Dispos. 2013 Feb;41(2):291-5. doi: 10.1124/dmd.112.049197. Epub 2012 Dec 4.

17.

Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.

Lévesque E, Beaulieu M, Green MD, Tephly TR, Bélanger A, Hum DW.

Pharmacogenetics. 1997 Aug;7(4):317-25.

PMID:
9295060
18.

Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.

Stringer F, Ploeger BA, DeJongh J, Scott G, Urquhart R, Karim A, Danhof M.

J Clin Pharmacol. 2013 Mar;53(3):256-63. doi: 10.1177/0091270012447121. Epub 2013 Jan 24.

PMID:
23444281
19.

Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.

Miyagi SJ, Milne AM, Coughtrie MW, Collier AC.

Drug Metab Dispos. 2012 Jul;40(7):1321-7. doi: 10.1124/dmd.111.043752. Epub 2012 Apr 5.

20.

Genetic variations in UDP-glucuronosyltransferase 2B15 in a Korean population.

Hwang MS, Lee SJ, Kim WY, Jeong HE, Shin JG.

Drug Metab Pharmacokinet. 2014;29(1):105-9. Epub 2013 Jul 23.

Supplemental Content

Support Center